| Excerpt | Relevance | Reference |
|---|
| "To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen." | 7.73 | Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. ( Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G, 2005) |
| "To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen." | 3.73 | Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. ( Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G, 2005) |